Mytos Announces Strategic Partnerships with StemSight, Rinri Therapeutics, and Novadip to Power Next-Generation Cell Therapy Trials
– Collaborations highlight the versatility of Mytos’ iDEM platform across diverse cell types and clinical applications from blindness and hearing loss to complex bone regeneration
LONDON–(BUSINESS WIRE)–Mytos, a biotechnology company automating cell manufacturing, today announced new manufacturing collaborations with three innovative biotech companies – StemSight, Rinri Therapeutics, and Novadip. Each company intends to integrate Mytos’ iDEM automated cell manufacturing platform to scale the production of diverse cell types for therapeutic use, highlighting the platform’s versatility to create cells to treat ocular diseases, hearing loss, and bone defects.
Related News
